Company / PP&E (Net)
C4 Therapeutics, Inc. PP&E (Net) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$4.7M
FY2025
5-year range
$4.7M / $7.4M
FY2022-FY2025
Trend
-18.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $7M in FY2022 to $5M in FY2025.
Based on SEC 10-K filings.
$5M in FY2025 with a 3-year CAGR of -13.8%.
Declined from $7M to $5M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- C4 Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 3-year CAGR of -13.8%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 18.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.7M | -18.8% |
| FY2024 | $5.8M | -18.1% |
| FY2023 | $7.1M | -3.6% |
| FY2022 | $7.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026